Company profile: Aethlon Medical
1.1 - Company Overview
Company description
- Provider of immunotherapeutic technologies to combat infectious disease and cancer, including the Hemopurifier, a device designed to rapidly remove cancer-promoting exosomes and circulating viruses from the bloodstream, currently under clinical trials for various cancers and viral infections.
Products and services
- Clinical-stage Hemopurifier Evaluation: Assessment across various cancers and viral infections, focused on rapid removal of cancer-promoting exosomes and circulating viruses from the bloodstream
- Hemopurifier: Clinical-grade device engineered to rapidly remove cancer-promoting exosomes and circulating viruses from the bloodstream, currently under clinical trials for various cancers and viral infections
- Immunotherapeutic Technology Development: Research-grade programs that develop immunotherapeutic technologies to combat infectious disease and cancer for patients.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aethlon Medical
Micreos
HQ: The Netherlands
Website
- Description: Provider of phage-based precision antimicrobials and engineered endolysins targeting pathogenic bacteria without harming the beneficial microbiome. Offerings include antimicrobial vectors; MEndoB for staphylococcal infections, including MRSA, for systemic/topical use; XZ.700 for S. aureus colonization in lesional skin (CTCL); and clinical/pre-clinical molecules for out-licensing, with focus areas including CTCL and AD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micreos company profile →
Inhibikase Therapeutics
HQ: United States
Website
- Description: Provider of cellular Abelson tyrosine kinase inhibitor therapeutics and platforms for infections and other diseases. Includes Risvodetinib (IkT-148009), an oral drug aimed at halting and reversing Parkinson’s progression in brain and GI; IkT-001Pro, a prodrug of imatinib mesylate for blood and stomach cancers with fewer on-dosing side effects; IkT-01427 to prevent PML; and the RAMP Drug Innovation Engine and Prodrug Delivery Technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inhibikase Therapeutics company profile →
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
T2 Biosystems
HQ: United States
Website
- Description: Provider of rapid, accurate infectious disease diagnostics, including the T2Dx Instrument, a fully automated system running tests directly from whole blood, the FDA-cleared T2Bacteria Panel for identifying sepsis-causing bacteria without blood culture, and T2Candida for detecting invasive candidiasis from whole blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T2 Biosystems company profile →
Abionic
HQ: Switzerland
Website
- Description: Provider of point-of-care diagnostic solutions at the boundaries of medical technology, biotechnology and nanotechnology, including abioSCOPE for rapid, accurate results from a single drop of blood; PSP Sepsis Test using Pancreatic Stone Protein for early sepsis detection; saliva-based SARS-CoV-2 antigen test; aeroallergen specific IgE panel; ferritin test for iron deficiency; and cSOFA COVID-19 severity score for triage and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aethlon Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aethlon Medical
2.2 - Growth funds investing in similar companies to Aethlon Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aethlon Medical
4.2 - Public trading comparable groups for Aethlon Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →